MRK ▲ +0.0% - Merck & Co., Inc. $MRK - Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan Merck received approval in Japan for a subcutaneous formulation of its cancer immunotherapy KEYTRUDA, expanding treatment options beyond the currently approved intravenous administration across all approved indications in the country. The subcutaneous version, marketed as KEYTRUDA QLEX, offers patients a more convenient alternative that could broaden accessibility and potentially drive future uptake in one of the world's largest pharmaceutical markets. 21-SEP-2026 06:54 AM ET